FIELD: biotechnology.
SUBSTANCE: disclosed are bispecific antigen-binding polypeptides which specifically bind to human PDGFRβ and human HER2. Present invention also relates to nucleic acids coding antigen-binding polypeptides, recombinant expression vectors and host cells for producing such antigen-binding polypeptides. Methods of using antigen-binding polypeptides of the present invention for treating a disease (e.g. cancer) are also encompassed by the present invention.
EFFECT: invention provides binding with PDGFRβ and HER2 with high degree of affinity.
19 cl, 12 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR TREATING BILE DUCT CANCER | 2019 |
|
RU2819802C2 |
| ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR AND APPLICATION THEREOF | 2019 |
|
RU2778023C1 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 | 2014 |
|
RU2737882C2 |
| BISPECIFIC ANTIBODIES TO CCL2 | 2020 |
|
RU2819613C1 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
